GSK Yönetim

Yönetim kriter kontrolleri 2/4

GSK CEO'su Luke Miels, Jan2026 tarihinde atandı, in görev süresi bir yıldan az. şirketin hisselerinin 0.007% doğrudan sahiptir ve bu hisselerin değeri $ 8.25M dir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 4.5 yıl ve 3.7 yıldır.

Anahtar bilgiler

Luke Miels

İcra Kurulu Başkanı

n/a

Toplam tazminat

CEO maaş yüzdesi	n/a
CEO görev süresi	less than a year
CEO sahipliği	0.007%
Yönetim ortalama görev süresi	4.5yrs
Yönetim Kurulu ortalama görev süresi	3.7yrs

Son yönetim güncellemeleri

Recent updates

CEO

Luke Miels (51 yo)

less than a year

Görev süresi

Mr. Luke Victor Miels has been the Chief Executive Officer & Director at GSK plc since January 01, 2026 and served as its Chief Commercial Officer from September 4, 2017 to January 01, 2026 and served as i...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Julie Brown	CFO & Executive Director	3yrs	UK£9.73m	0.0042% $ 4.9m
Emma Walmsley	Executive Officer	less than a year	UK£15.68m	0% $ 0
Jesse Goodman	Scientific & Medical Expert	no data	UK£61.57k	Veri yok
Luke Miels	CEO & Director	less than a year	Veri yok	0.0070% $ 8.2m
Shobie Ramakrishnan	Chief Digital & Technology Officer	5.3yrs	Veri yok	Veri yok
Tony Wood	Chief Scientific Officer and Head of R&D	3.7yrs	Veri yok	Veri yok
Constantin Fest	Senior VP & Head of Investor Relations	no data	Veri yok	Veri yok
James Ford	Senior VP and Group General Counsel of Legal & Compliance	7.7yrs	Veri yok	Veri yok
David Redfern	President of Corporate Development	no data	Veri yok	Veri yok
Diana Conrad	Chief People Officer	7yrs	Veri yok	Veri yok
Philip Thomson	President of Global Affairs	9yrs	Veri yok	0.0082% $ 9.6m
Regis Simard	President of Global Supply Chain	no data	Veri yok	Veri yok

4.5yrs

Ortalama Görev Süresi

56yo

Ortalama Yaş

Deneyimli Yönetim: GLAX.F 'un yönetim ekibi deneyimli olarak değerlendirilmektedir (ortalama görev süresi 4.5 yıldır).

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Julie Brown	CFO & Executive Director	2.9yrs	UK£9.73m	0.0042% $ 4.9m
Luke Miels	CEO & Director	less than a year	Veri yok	0.0070% $ 8.2m
Jonathan Symonds	Chair	6.6yrs	UK£833.00k	0.0023% $ 2.7m
Vishal Sikka	Independent Non-Executive Director	3.8yrs	UK£179.52k	0.00062% $ 726.1k
Hal Barron	Non-Executive Director	8.3yrs	UK£342.73k	0.033% $ 39.0m
Harry Dietz	Independent Non-Executive Director	4.3yrs	UK£210.68k	0.00024% $ 281.1k
Anne Beal	Independent Non-Executive Director	4.9yrs	UK£183.97k	0.00025% $ 292.8k
Wendy Mira Becker	Independent Non-Executive Director	2.5yrs	UK£202.00k	0.00020% $ 234.2k
Charles Bancroft	Senior Independent Non-Executive Director	5.9yrs	UK£262.61k	0.0020% $ 2.4m
Gavin Screaton	Independent Non-Executive Director	less than a year	UK£108.00k	0.00037% $ 433.3k
Tsun-Huei Lee	Independent Non-Executive Director	2.1yrs	UK£166.17k	0.00010% $ 117.1k
Elizabeth Anderson	Independent Non-Executive Director	3.6yrs	UK£148.37k	0.00017% $ 199.1k

3.7yrs

Ortalama Görev Süresi

63yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: GLAX.F 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 3.7 yıldır).

Şirket Analizi ve Finansal Veri Durumu

Veri	Son Güncelleme (UTC saati)
Şirket Analizi	2026/04/12 07:00
Gün Sonu Hisse Fiyatı	2026/04/10 00:00
Kazançlar	2025/12/31
Yıllık Kazançlar	2025/12/31

Veri Kaynakları

Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.

Paket	Veri	Zaman Çerçevesi	Örnek ABD Kaynağı ^*
Şirket Finansalları	10 yıl	Gelir tablosu Nakit akış tablosu Bilanço	SEC Form 10-K SEC Form 10-Q
Analist Konsensüs Tahminleri	+3 yıl	Finansal tahminler Analist fiyat hedefleri	Analist Araştırma Raporları Blue Matrix
Piyasa Fiyatları	30 yıl	Hisse senedi fiyatları Temettüler, Bölünmeler ve Eylemler	ICE Piyasa Verileri SEC Form S-1
Sahiplik	10 yıl	En büyük hissedarlar İçeriden öğrenenlerin ticareti	SEC Form 4 SEC Form 13D
Yönetim	10 yıl	Liderlik ekibi Yönetim Kurulu	SEC Form 10-K SEC Form DEF 14A
Önemli Gelişmeler	10 yıl	Şirket duyuruları	SEC Form 8-K

* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılmıştır.

Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Daha fazla bilgi edinin.

Analiz Modeli ve Kar Tanesi

Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntılarına GitHub sayfamızdan ulaşabilirsiniz, ayrıca raporlarımızı nasıl kullanacağınızı anlatan kılavuzlarımız ve Youtube'da eğitim videolarımız da bulunmaktadır.

Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.

Endüstri ve Sektör Metrikleri

Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları Github'da mevcuttur.

Analist Kaynakları

GSK plc 46 Bu analistlerden 19, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.

Analist	Kurum
John Eade	Argus Research Company
Odile Rundquist	Baader Helvea Equity Research
James Gordon	Barclays

GSK Yönetim

Yönetim kriter kontrolleri 2/4

Anahtar bilgiler

Son yönetim güncellemeleri

GSK plc, Annual General Meeting, May 06, 2026

GSK plc Appoints Elizabeth McKee Anderson as Member of the Corporate Responsibility Committee, Effective March 9, 2026

GSK plc Appoints Luke Victor Miels as Director, Effective January 1, 2026

GSK plc, Annual General Meeting, May 07, 2025

GSK plc Announces Board and Committee Changes

Recent updates

GSK plc Announces Exdensur Approval for CRSwNP in China

Samsung Biologics America, Inc completed the acquisition of Human Genome Sciences Inc. from GSK plc (LSE:GSK).

Bepirovirsen Accepted for Regulatory Review in China as A Potential First-In-Class Functional Cure for Chronic Hepatitis B

GSK PLC Bepirovirsen Accepted For Review By The European Medicines Agency As A Potential First-In-Class Treatment For Chronic Hepatitis B

GSK plc, Annual General Meeting, May 06, 2026

US Food and Drug Administration Approves GSK plc's Lynavoy(linerixibat)

GSK plc Announces Expansion of AREXVY Approval to Adults Aged 18 to 49 Years for RSV Prevention

Angeion Group Announces Proposed Settlement in DeCostanzo v. GlaxoSmithKline

GSK plc Appoints Elizabeth McKee Anderson as Member of the Corporate Responsibility Committee, Effective March 9, 2026

GSK plc (LSE:GSK) completed the acquisition of 93.4% stake in RAPT Therapeutics, Inc. (NasdaqGM:RAPT) for $1.7 billion.

GSK plc Announces That Japan's Ministry of Health, Labour and Welfare Accepts for Review A New Drug Application for Bepirovirsen

GSK plc (LSE:GSK) entered an agreement to acquire 35Pharma Inc for CAD 950 million.

GSK plc Announces New Effectiveness Data for AREXVY (Respiratory Syncytial Virus Vaccine, Adjuvanted) At RSVVW'26

GSK plc's RSV Vaccine Accepts for Review by China's Center for Drug Evaluation for the Prevention of Lower Respiratory Syncytial Virus Disease

GSK plc Announces Nucala (Mepolizumab) Approval by European Commission for Treatment of Chronic Obstructive Pulmonary Disease (COPD)

Gsk Plc's Rsv Vaccine Receives European Approval for Expanded Use in All Adults 18 Years and Older

GSK plc (LSE:GSK) entered a definitive agreement to acquire RAPT Therapeutics, Inc. (NasdaqGM:RAPT) for $1.7 billion.

GSK plc to Report Q4, 2025 Results on Feb 04, 2026

GSK plc Appoints Luke Victor Miels as Director, Effective January 1, 2026

GSK plc Announces Positive Topline Results from B-Well 1 and B-Well 2 Phase 3 Studies for Bepirovirsen

GSK plc Announces the Approval of Exdensur ( Depemokimab) by Japan's Ministry of Health, Labour and Welfare

GSK plc Announces China's National Medical Products Administration Approval of Nucala (Mepolizumab) as Add-On Maintenance Treatment of Adult Patients with Inadequately Controlled COPD

Samsung Biologics America, Inc. entered into a definitive agreement to acquire Human Genome Sciences Inc. from GSK plc (LSE:GSK) for $280 million.

Spero Therapeutics, Inc. Announces Nda Resubmission of Tebipenem Hbr by Gsk to the Fda for the Treatment of Complicated Urinary Tract Infections, Including Pyelonephritis

GSK plc Announces Exdensur (depemokimab) Approved by US FDA for the Treatment of Severe Asthma

GSK plc Announces the Marketing Authorisation of Exdensur ( Depemokimab) by the UK's Medicines and Healthcare Products Regulatory Agency

GSK plc Announces US FDA Approval Of Blujepa For Gonorrhoea Indication

GSK plc Receives Orphan Drug Designation from US Food and Drug Administration for the Treatment of Small-Cell Lung Cancer

GSK plc Upgrades Earnings Guidance for the Year Ending December 31, 2025

GSK plc Announces US FDA Approves Blenrep (Belantamab Mafodotin-Blmf) in Combination with Bortezomib and Dexamethasone (BVd) for Treatment of Adult Patients with Relapsed or Refractory Multiple Myeloma

GSK plc Announces Positive Phase III Data for Next-Generation Low Carbon Version of Ventolin Metered Dose Inhaler

GSK's Shingrix New Prefilled Syringe Presentation Receives Positive CHMP Opinion

GSK's Shingrix Approved in China for Prevention of Shingles in Adults Aged 18 and over Who are at Increased Risk Due to Immunodeficiency or Immunosuppression

GSK plc to Report Q3, 2025 Results on Oct 29, 2025

GSK plc Announces Major Update to Vaccine Track

US Food and Drug Administration Accepts GSK plc's Gepotidacin as an Oral Option for the Treatment of Unplicated Urogenital Grogenital Grogenital Gonorrhoea

GSK plc Provides Update on US Settlement of CureVac/BioNTech mRNA Patent litigation

GSK plc Declares Second Interim Dividend for Second Quarter of 2025, Payable on 9 October 2025

GSK plc Announces Blenrep (Belantamab Mafodotin) Combinations Approved in EU for Treatment of Relapsed/Refractory Multiple Myeloma

GSK plc Provides Update on US FDA Advisory Committee Review of Blenrep (belantamab Mafodotin-blmf) Combinations

US FDA Accepts Application to Review Expanded Use of GSK's RSV Vaccine, Arexvy, for Adults 18-49 At Increased Risk

GSK plc (LSE:GSK) completed the acquisition of Efimosfermin alfa drug from Boston Pharmaceuticals Inc.

GSK plc Announces FDA Approves Benlysta (belimumab) Autoinjector for Children with Active Lupus Nephritis

Gsk plc Announces Japan's Ministry of Health, Labour and Welfare Accepts Regulatory Application to Expand Use of Gsk's Rsv Vaccine

GSK plc Announces the Linked by Lupus: Optimal Care Initiative to Help Support Individuals with Lupus in the US

GSK plc's RSV Vaccine Accepts for Regulatory Review by the European Medicines Agency to Expand Use in Adults 18 Years and Older

GSK plc announces the US Food and Drug Administration has accepted for review the NDA for linerixibat

GSK plc and Spero Therapeutics Announces PIVOT-PO Phase III Study for Tebipenem HBr Starts Early for Efficacy

GSK plc Announces Blenrep (Belantamab Mafodotin) Combination Receive Positive CHMP Opinion in Relapsed/Refractory Multiple Myeloma

GSK plc Announces Approval Ofenrep Combinations by Japan's Ministry of Health, Labour and Welfare for the Treatment of Adults with Relapsed/Refractory Multiple Myeloma

GSK plc (LSE:GSK) agreed to acquire Efimosfermin alfa drug from Boston Pharmaceuticals Inc. for $2 billion.

GSK plc Announces Positive Results for Nucala

GSK plc Announces the Authorisation of Blenrep by the Medicines and Healthcare Products Regulatory Agency

GSK plc Recommends the Use of RSV Vaccines Including GSK'sAREXVY (Respiratory Syncytial Virus Vaccine, Adjuvanted)

GSK plc to Report Q1, 2025 Results on Apr 30, 2025

GSK's Omjjara (Momelotinib) Approves in Singapore as the First Treatment Indicated for Myelofibrosis Patients with Anaemia

GSK plc, Annual General Meeting, May 07, 2025

US Food and Drug Administration Accepts Depemokimab Application for the Use of D Epemokimab in Two Indications

GSK plc (LSE:GSK) announces an Equity Buyback for £2,000 million worth of its shares.

GSK plc (LSE:GSK) completed the acquisition of IDRX, Inc. from a group of shareholders.

GSK plc Announces That The Chinanational Medical Products Administration Has Accepted for Review the New Drug Application for the Use of Nucala (Mepolizumab)

GSK plc Announces Board and Committee Changes

Gsk plc Announces Approval of Penmenvy, Gsk’S 5-In-1 Meningococcal Vaccine by US FDA

GSK plc Provides Earnings Guidance for the Full-Year of 2025; Provides Earning Guidance for 2026

Bernstein Litowitz Berger & Grossmann LLP Announces the Filing of Securities Class Action Lawsuit Against GSK plc

GSK plc Announces Acceptancy of Depemokimab Applications for Review in China and Japan for Asthma with Type 2 Inflammation and CRSwNP

Gsk plc Announces the European Medicines Agency Accepts for Review the Regulatory Application of A Prefilled Syringe Presentation of Shingrix

GSK plc Announces the European Commission Approval to Expand the Use of Jemperli Plus Chemotherapy (Caroplatin and Paclitaxel) for First-Line Treatment of Adult Patients with Primary Advanced or Recurrent Endometrial Cancer

GSK plc to Report Q4, 2024 Results on Feb 05, 2025

GSK plc (LSE:GSK) entered into an agreement to acquire IDRX, Inc. from a group of shareholders for approximately $1.2 billion.